Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KNT-0916
- Development stage
- Phase 1
- Lead developer
- KinoTeck Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KNT-0916 is an oral, small molecule inhibitor targeting the type 2 fibroblast growth factor receptor (FGFR2). It is being developed for the treatment of unresectable or metastatic solid tumors harboring FGFR2 alterations. The drug acts as an FGFR2 antagonist, aiming to block aberrant signaling pathways associated with tumor growth and progression in cancers with FGFR2 abnormalities. Clinical development is currently at Phase 1, focusing on evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients who have failed prior systemic therapy[1][2][3][4].
02
Targets
FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on KNT-0916.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KNT-0916.